In the immuno-oncology space, the regulation of the immune system is paramount in the development of a successful therapeutic. This webinar will showcase assays to evaluate cellular pathways of immune cells, T-cells, and macrophages while highlighting functional and immunogenicity assays developed in support of current and emerging therapeutics. The speakers, Sofie Pattijn, an immuno-oncology expert who leads the ImmunXperts team in Belgium, and Thibaut Janss, one of their leading expert scientists for immuno-oncology, will outline how in vitro methods mimic the tumor environment to measure therapeutic functionality.
Register for this webinar to hear the speakers highlight how in vitro models are essential at critical phases of development to support lead candidate selection or generate data for evaluation in an exploratory clinical phase. As the development transitions through pre-IND to clinical phases, there are a variety of cellular assays and clinical applications that support the drug development process.
Sofie Pattijn, CTO and Co-Founder, ImmunXperts, a Nexelis Company
Sofie Pattijn, Chief Technology Officer and Founder of ImmunXperts, has over 20 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics) and in vitro assay development with a focus on functional assays for immunogenicity, immuno-oncology, and cell and gene therapy products. She has extensive hands-on lab experience and has managed and coached several in vitro teams over the last decade. From 2008 to 2013, Sofie was head of the in vitro immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics in Belgium for over 15 years.Message Presenter
Thibaut Janss, Lead Scientist, ImmunXperts, a Nexelis Company
Thibaut Janss holds a Master’s degree in Biochemistry, Molecular and Cellular Biology from the University of Liège. He received his PhD (2012-2016) at the GIGA Research Center in Liège, where he acquired extensive experience in the immunology field, working on dendritic cells and T cells interactions. During this period, he also developed an in-depth knowledge of flow cytometry. He joined ImmunXperts at the beginning of 2017 and is currently leading the immuno-oncology team.Message Presenter
Who Should Attend?
- Applicable to people in the early development to lead selection phase focused on immunogenicity for immunotherapies or immuno-oncology
- Scientists involved with development into the clinical trial phase who need more information on the immunogenicity and functional immune response through exploratory endpoints
What You Will Learn
In this webinar, participants will learn about:
- How to evaluate in vitro functional assays to illicit an immune response for oncology therapeutic targets
- Assays that support and bolster immuno-oncology development for clinical applications studying exploratory endpoints
- How clinical applications that utilize flow cytometry can improve the drug development process
Nexelis is your partner for assay and biomarker development, advanced bioanalytical and laboratory testing, and translational immunology. As the leading specialty laboratory, we have unrivaled expertise in immunology, specifically in the areas of infectious diseases, vaccine development, metabolic diseases, and immuno-oncology. Across five operating sites in North America and Europe, we integrate our technology platforms and offer translational solutions from early development through late stage clinical. Our deep bench of scientists are instrumental in development and large-scale sample testing of new modalities. These future therapies include blockbuster vaccines and biologics, antiviral drugs, immunotherapies, and gene and cell therapy products. Through our scientific discipline, critical thinking, and agility, we provide smarter solutions that produce scientifically sound data consistently to advance your molecule to market. To learn more, visit www.Nexelis.com.